Vise Technologies Inc. Takes Position in DexCom, Inc. $DXCM

Vise Technologies Inc. purchased a new stake in shares of DexCom, Inc. (NASDAQ:DXCM) during the second quarter, Holdings Channel reports. The institutional investor purchased 2,627 shares of the medical device company’s stock, valued at approximately $229,000.

Other hedge funds have also bought and sold shares of the company. Brighton Jones LLC lifted its position in shares of DexCom by 257.7% during the fourth quarter. Brighton Jones LLC now owns 16,582 shares of the medical device company’s stock worth $1,290,000 after acquiring an additional 11,946 shares in the last quarter. Kestra Private Wealth Services LLC raised its stake in shares of DexCom by 18.5% during the 1st quarter. Kestra Private Wealth Services LLC now owns 13,086 shares of the medical device company’s stock valued at $894,000 after purchasing an additional 2,039 shares during the period. Teachers Retirement System of The State of Kentucky lifted its holdings in DexCom by 16.7% during the 1st quarter. Teachers Retirement System of The State of Kentucky now owns 136,968 shares of the medical device company’s stock worth $9,353,000 after purchasing an additional 19,607 shares in the last quarter. Los Angeles Capital Management LLC boosted its stake in DexCom by 287.0% in the 1st quarter. Los Angeles Capital Management LLC now owns 313,796 shares of the medical device company’s stock worth $21,429,000 after purchasing an additional 232,705 shares during the period. Finally, Peterson Wealth Services grew its holdings in DexCom by 16.3% during the 1st quarter. Peterson Wealth Services now owns 3,524 shares of the medical device company’s stock valued at $241,000 after buying an additional 494 shares in the last quarter. 97.75% of the stock is currently owned by hedge funds and other institutional investors.

DexCom Stock Performance

NASDAQ DXCM opened at $58.49 on Tuesday. DexCom, Inc. has a 52-week low of $54.11 and a 52-week high of $93.25. The company has a fifty day moving average of $66.86 and a 200-day moving average of $77.17. The company has a market capitalization of $22.81 billion, a P/E ratio of 40.62, a P/E/G ratio of 1.43 and a beta of 1.40. The company has a debt-to-equity ratio of 0.48, a quick ratio of 1.35 and a current ratio of 1.52.

DexCom (NASDAQ:DXCM) last issued its quarterly earnings results on Thursday, October 30th. The medical device company reported $0.61 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.57 by $0.04. DexCom had a return on equity of 30.41% and a net margin of 13.29%.The firm had revenue of $1.21 billion during the quarter, compared to analyst estimates of $1.18 billion. During the same quarter in the previous year, the company posted $0.45 earnings per share. The company’s revenue was up 21.6% compared to the same quarter last year. DexCom has set its FY 2025 guidance at EPS. As a group, equities research analysts predict that DexCom, Inc. will post 2.03 EPS for the current fiscal year.

Insider Buying and Selling

In other news, COO Jacob Steven Leach bought 18,200 shares of the business’s stock in a transaction on Monday, November 10th. The stock was acquired at an average price of $55.04 per share, with a total value of $1,001,728.00. Following the completion of the purchase, the chief operating officer directly owned 331,697 shares in the company, valued at $18,256,602.88. This represents a 5.81% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, EVP Sadie Stern sold 1,466 shares of the stock in a transaction that occurred on Thursday, September 4th. The shares were sold at an average price of $80.00, for a total transaction of $117,280.00. Following the transaction, the executive vice president owned 105,223 shares in the company, valued at $8,417,840. The trade was a 1.37% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 9,999 shares of company stock worth $619,391 over the last ninety days. Corporate insiders own 0.32% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on DXCM shares. Barclays set a $80.00 price target on shares of DexCom and gave the stock an “equal weight” rating in a report on Monday, November 3rd. Stifel Nicolaus began coverage on shares of DexCom in a research note on Tuesday, October 21st. They issued a “buy” rating and a $85.00 target price on the stock. Morgan Stanley cut their price target on shares of DexCom from $89.00 to $63.00 and set an “equal weight” rating for the company in a report on Monday, November 10th. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of DexCom in a report on Wednesday, October 8th. Finally, Argus lowered their price objective on DexCom from $100.00 to $90.00 and set a “buy” rating on the stock in a research report on Friday, November 7th. Three investment analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and six have given a Hold rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $87.62.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.